Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation

Circulation: Cardiovascular Quality and Outcomes

Volumn 2, Issue 5, 2009, Pages 429-436

  Patrick, Amanda R ^a   Avorn, Jerry ^a   Choudhry, Niteesh K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anticoagulants; Arrhythmias; Cardiac; Cost benefit analysis; Genetics

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ARTICLE; BLEEDING DISORDER; BRAIN ISCHEMIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG FATALITY; ECONOMIC EVALUATION; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; GROUPS BY AGE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; BLEEDING; CHEMICALLY INDUCED DISORDER; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; GENETIC SCREENING; GENETICS; INCIDENCE; MORTALITY; PERSONALIZED MEDICINE; PROBABILITY; QUALITY OF LIFE; STATISTICAL MODEL; STROKE;

AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; COST-BENEFIT ANALYSIS; DRUG COSTS; GENETIC TESTING; GENOTYPE; HEMORRHAGE; HUMANS; INCIDENCE; INDIVIDUALIZED MEDICINE; MARKOV CHAINS; MIXED FUNCTION OXYGENASES; MODELS, ECONOMETRIC; QUALITY OF LIFE; STROKE; WARFARIN;

EID: 71649099370     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.108.808592     Document Type: Article

References (50)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
2. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.
3. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2004;91:87-94.
4. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353: 717-719.
5. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358: 999-1008.
6. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287:1690-1698.
7. Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost. 2000;84:775-778.
8. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285-2293.
9. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106:2329-2333.
10. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116: 2563-2570.
11. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008;83: 460-470.
12. New Labeling Information for Warfarin. Available at: http://www.fda.gov/ cder/drug/infopage/warfarin/default.htm. Accessed January 10, 2008.
13. Harvard Medical School Partners Center for Genetics and Genomics. Warfarin Metabolism Panel: VKORC1 Haplotype A vs. B, CYP2C9 *2 and *3 Available at: http://www.hpcgg.org/LMM/comment/warfarin%20info%20sheet. jsp?name-LMM&subname-genetictests. Accessed May 29, 2008.
14. Genelex. Prevent warfarin "oversteer" with DNA testing. Available at: http://www.healthanddna.com/professional/anticoagulation.html. Accessed May 29, 2008.
15. McWilliams A, Lutter R, Nardinelli C. Health care savings from personalizing medicine using genetic testing: the case for warfarin. AEIBrookings Joint Center for Regulatory Studies; 2006.
16. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
17. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
18. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002;22:417-430.
19. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146: 473-481.
20. Center for the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry ICRHPS, Tufts Medical Center.
21. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689-2696.
22. Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgelski AE. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med. 2002;113:42-51.
23. Evans A, Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med. 2001;161:1443-1447.
24. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res. 2006;118:321-333.
25. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019-1026.
26. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285:2864-2870.
27. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
28. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164:880-884.
29. Agency for Healthcare Research and Quality. 2003 Nationwide Inpatient Sample. Healthcare Cost and Utilization Project: Rockville, Md; 2003.
30. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685-2692.
31. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897-902.
32. Thomson Healthcare (Firm). Red book. Montvale, NJ: Thomson PDR; 2007:v.
33. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005;293:699-706.
34. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829-1836.
35. Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, Tsang TS. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol. 2007;49: 986-992.
36. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Seward JB, Bailey KR, Iwasaka T, Tsang TS. Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. Stroke. 2005;36:2362-2366.
37. Frost L, Vestergaard P, Mosekilde L, Mortensen LS. Trends in incidence and mortality in the hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980-1999. Int J Cardiol. 2005;103:78-84.
38. Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med. 2000;109:481-488.
39. Centers for Medicare and Medicaid Services. Last year of life expenditures. 2003.
40. Pope GC, Kautter J, Ellis RP, Ash AS, Ayanian JZ, Lezzoni LI, Ingber MJ, Levy JM, Robst J. Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financing Review. 2004;25: 119-141.
41. Consumer Price Index: Medical Care Component. Bureau of Labor Statistics, U.S. Department of Labor.
42. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Medical Care. 2005;43:736-749.
43. Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value in Health. 2005;8:2.
44. Leavitt MO, Kucherlapati R. The great promise of personalized medicine. The Boston Globe, 2008.
45. Schalekamp T, Boink GJ, Visser LE, Stricker BH, de Boer A, Klungel OH. CYP2C9 genotyping in acenocoumarol treatment: is it a costeffective addition to international normalized ratio monitoring? Clin Pharmacol Ther. 2006;79:511-520.
46. You JH, Chan FW, Wong RS, Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis. Thromb Haemost. 2004;92: 590-597.
47. McWilliams A, Lutter R, Nardinelli C. Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin. Personalized Med. 2008;5:6.
48. Veenstra DL. The cost-effectiveness of warfarin pharmacogenomics. J Thromb Haemost. 2007;5:1974-1975.
49. Pollack A. Gene Test for Dosage of Warfarin is Rebuffed. The New York Times. May 5, 2009.
50. Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, Glurich I, Berg RL, Schmelzer J, Burmester JK. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med REs. 2005;3:137-145.